AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie humira (adalimumab) — U.S. net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, Q2 2026
425
Period ended Jun 30, 2026
Change on a year earlier
-47.0%
802 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
33
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Humira (adalimumab) — U.S. net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 425 | -47.0% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2026 | Mar 31, 2026 | 357 | -52.0% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 897 | -28.0% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 619 | -64.9% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 802 | -66.0% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2025 | Mar 31, 2025 | 744 | -58.0% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2024 | Dec 31, 2024 | 1,246 | -54.5% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,765 | -41.6% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 2,360 | -31.6% | Form 10-Q (filed 2025-08-04) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,771 | -39.9% | Form 10-Q (filed 2025-05-09) ↗ |
| Q4 2023 | Dec 31, 2023 | 2,740 | -45.3% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2023 | Sep 30, 2023 | 3,020 | -39.1% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2023 | Jun 30, 2023 | 3,452 | -26.0% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 2,948 | -26.2% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 5,006 | +9.9% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2022 | Sep 30, 2022 | 4,956 | +7.4% | Form 10-Q (filed 2023-11-06) ↗ |
| Q2 2022 | Jun 30, 2022 | 4,664 | +9.6% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2022 | Mar 31, 2022 | 3,993 | +2.2% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2021 | Dec 31, 2021 | 4,553 | +6.1% | Form 10-K (filed 2024-02-20) ↗ |
| Q3 2021 | Sep 30, 2021 | 4,613 | +10.1% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 4,257 | +7.1% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 3,907 | +6.9% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 4,293 | +8.2% | Form 10-K (filed 2023-02-17) ↗ |
| Q3 2020 | Sep 30, 2020 | 4,189 | +7.8% | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2020 | Jun 30, 2020 | 3,974 | +4.8% | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2020 | Mar 31, 2020 | 3,656 | +13.7% | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 3,969 | +9.8% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2019 | Sep 30, 2019 | 3,887 | +9.6% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2019 | Jun 30, 2019 | 3,793 | +7.7% | Form 10-Q (filed 2020-08-04) ↗ |
| Q1 2019 | Mar 31, 2019 | 3,215 | +7.1% | Form 10-Q (filed 2020-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 3,615 | +9.1% | Form 10-K (filed 2021-02-19) ↗ |
| Q3 2018 | Sep 30, 2018 | 3,546 | +12.5% | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 3,521 | +10.0% | Form 10-Q (filed 2019-08-05) ↗ |
| Q1 2018 | Mar 31, 2018 | 3,003 | +11.4% | Form 10-Q (filed 2019-05-03) ↗ |
| Q4 2017 | Dec 31, 2017 | 3,313 | – | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2017 | Sep 30, 2017 | 3,151 | – | Form 10-Q (filed 2018-11-07) ↗ |
| Q2 2017 | Jun 30, 2017 | 3,201 | – | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2017 | Mar 31, 2017 | 2,696 | – | Form 10-Q (filed 2018-05-04) ↗ |
Breakdown
What makes up humira (adalimumab) — u.s. net revenues ($m)
Cite this data
StockData. (2026). AbbVie Humira (adalimumab) — U.S. net revenues ($M) ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/humira_us
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.